Showing results (1-10 of 55) with videos related to
Sort By:
Pageof 6
Urologie (Heidelberg, Germany)|February 22, 2023
[Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer]Martin BoegemannMini Reviews in Medicinal Chemistry|May 14, 2016
Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder CancerMartin Boegemann, Laura-Maria KrabbeAktuelle Urologie|February 8, 2019
[Update Urooncology: News from major scientific meetings 2018]Hendrik Heers, Martin Boegemann, Axel HegeleCurrent Cancer Drug Targets|February 6, 2015
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)Martin Boegemann, Andres-Jan Schrader, Laura-Maria Krabbe, et al.Expert Opinion on Biological Therapy|August 24, 2017
Prospects and progress of immunotherapy for bladder cancerMartin Boegemann, Ahmet Murat Aydin, Aditya Bagrodia, et al.Health Informatics Journal|June 27, 2019
Combination possibility and deep learning model as clinical decision-aided approach for prostate cancerOkyaz Eminaga, Omran Al-Hamad, Martin Boegemann, et al.Expert Review of Anticancer Therapy|January 20, 2016
The safety and efficacy of gemcitabine for the treatment of bladder cancerKatrin Schlack, Martin Boegemann, Julie Steinestel, et al.BMC Cancer|April 9, 2022
The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamideRenata Poteska, Kambiz Rahbar, Axel Semjonow, et al.Theranostics|August 15, 2019
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617Katharina Kessel, Robert Seifert, Michael Schäfers, et al.Pageof 6